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ABSTRACT
Bisphosphonates arewidelyused in the treatmentof clinical disorders characterizedby increasedbone resorption, includingosteoporosis,
Paget’s disease, and the skeletal complications ofmalignancy. The antiresorptive potency of the nitrogen-containingbisphosphonates on
bone in vivo is now recognized to depend upon two key properties, namely mineral binding afﬁnity and inhibitory activity on farnesyl
pyrophosphate synthase (FPPS), and these properties vary independently of each other in individual bisphosphonates. The better
understanding of structure activity relationships among the bisphosphonates has enabled us to design a series of novel bisphosphonates
with a range of mineral binding properties and antiresorptive potencies. Among these is a highly potent bisphosphonate, 1-ﬂuoro-2-
(imidazo-[1,2 alpha]pyridin-3-yl)-ethyl-bisphosphonate, also known as OX14, which is a strong inhibitor of FPPS, but has lower binding
afﬁnity for bone mineral than most of the commonly studied bisphosphonates. The aim of this work was to characterize OX14
pharmacologically in relation to several of the bisphosphonates currently used clinically.WhenOX14was compared to zoledronate (ZOL),
risedronate (RIS), and minodronate (MIN), it was as potent at inhibiting FPPS in vitro but had signiﬁcantly lower binding afﬁnity to
hydroxyapatite (HAP) columns thanALN, ZOL, RIS, andMIN.When injected i.v. into growing SpragueDawley rats, OX14was excreted into
the urine to a greater extent than the other bisphosphonates, indicating reduced short-term skeletal uptake and retention. In studies in
both Sprague Dawley rats and C57BL/6J mice, OX14 inhibited bone resorption, with an antiresorptive potency equivalent to or greater
than the comparator bisphosphonates. In the JJN3-NSGmurine model of myeloma-induced bone disease, OX14 signiﬁcantly prevented
the formation of osteolytic lesions (p< 0.05). In summary, OX14 is a new, highly potent bisphosphonate with lower bone binding afﬁnity
than other clinically relevant bisphosphonates. This renders OX14 an interesting potential candidate for further development for its
potential skeletal and nonskeletal beneﬁts. © 2017 The Authors. Journal of Bone and Mineral Research Published byWiley Periodicals Inc.
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Introduction
Bisphosphonates continue to be the major drugs used in theprevention and treatment of diseases or conditions character-
ized by increased bone resorption, including osteoporosis and
Paget’s disease. They are also used to prevent the skeletal
complications of malignancy in breast, prostate, and other
cancers, as well as in multiple myeloma, and may increase the
survival of patients with some of these cancers.(1,2) Zoledronate
(ZOL, also often known as zoledronic acid, ZA) is given intravenously
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(i.v.) rather than orally, provides the standard of care for many
of these conditions, and is used especially in bone oncology.
The ﬁrst bisphosphonates to be developed for clinical use,
etidronate, clodronate, pamidronate, and alendronate (ALN),
were already known chemical compounds.(3) Subsequently,
medicinal chemists synthesized literally hundreds of compounds
from which the next generation of successful bisphosphonates
were chosen, notably risedronate (RIS), ibandronate (IBN), and
ZOL.(4,5) These bisphosphonates emerged from screening pro-
grams and were selected based on their potency and safety
proﬁles, but in an era before the detailed molecular mechanisms
of action of bisphosphonates were elucidated.
The antiresorptivepotencyof thenitrogen-containingbisphosph-
onates on bone in vivo is now recognized to depend upon two key
properties, namelymineral binding afﬁnity and inhibitory activity on
farnesyl pyrophosphate synthase (FPPS); these properties vary
independently of each other in individual bisphosphonates.(6)
This better understanding of structure activity relationships
among the bisphosphonates has enabled us to design a series of
novel bisphosphonates with a range of mineral binding properties
and inhibitory potencies on FPPS. During the past decade we have
synthesizeddozensofnewbisphosphonates, and screened them for
these properties. Among these is a highly potent bisphosphonate
with reduced afﬁnity for bone mineral, namely 1-ﬂuoro-2-(imidazo-
[1,2 alpha]pyridin-3-yl)-ethyl-bisphosphonate, also knownasOX14(7)
(see the Supporting Materials and Methods for further details of
synthesis and structure). Theaimof theworkdescribedhereinwas to
characterize OX14 pharmacologically, and to compare it to other
bisphosphonates currently used clinically.
There are several reasons why bisphosphonates with reduced
bonebindingcharacteristics,but retainingstrong inhibitoryactivity
on FPPS, might have potential value. Such compounds, like RIS,
have a more rapidly reversible effect on reducing bone turnover
compared with longer-acting bisphosphonates such as ALN and
ZOL. Thismay have advantages under certain circumstances; eg, in
treating women of childbearing years. Furthermore, the risk of
some of the side effects that are often attributed to long-term
bisphosphonate treatment, such as osteonecrosis of the jaw(8–10)
andatypical femoral factures,(11–14)maybeminimized.Withinbone
itself, a bisphosphonate that detaches from bone surfaces more
readily may have greater effects on cells within the marrow
microenvironment, including tumor cells, and may even have
beneﬁcial effects in more distal tissues. Indeed, bisphosphonate
treatment has been associated with a range of apparently
nonskeletal effects, including reductions in mortality,(15–17) a
reduction of myocardial infarctions,(18) and improved survival of
certainpatientgroups.(19–21)These considerationsprovideduswith
the rationale for studying the pharmacological proﬁle of OX14.
Materials and Methods
Ethics statement
All procedures involving mice were conducted at the
University of Shefﬁeld, UK, and were approved by the Home
Ofﬁce (PPL 40/3462) and the University of Shefﬁeld’s Animal
Ethics Committee in accordance with the Animal [Scientiﬁc
Procedures] Act 1986. All procedures involving rats were
conducted at the Procter & Gamble Health Sciences Center,
Mason, OH, USA. They were performed in accordance with the
guidelines of Procter & Gamble Pharmaceuticals’ Institutional
Animal Care and Use Committee, and meet the guidelines
established by the Animal Welfare Act.
Materials
The bisphosphonates were obtained from Procter and Gamble
Pharmaceuticals (FHE, Mason, OH, USA), except for ALN, which
was from Sigma (St. Louis, MO, USA), and OX14 (1-ﬂuoro-2-
(imidazo-[1,2-a]pyridin-3-yl)-ethyl-bisphosphonate), which was
synthesized by AM (see Supporting Materials and Methods for
details(7)).
Cell lines
The JJN3 myeloma cell line (originally derived from the bone
marrow of a 57-year-old woman with plasma cell leukemia at
diagnosis) was purchased from DSMZ (Braunschweig, Germany)
and grown in RPMI medium, containing 10% FCS, 1% penicillin/
streptomycin (100U/100mg/mL), 1% non-essential amino acids
(1), and 1% sodium pyruvate (1mM) at 37°C in 5% CO2
(Sigma–Aldrich, Dorset, UK). The cell linewas genetically proﬁled
by American Type Culture Collection (ATCC, Manassas, VA, USA)
using short tandem repeat analysis to conﬁrm its identity.
Animals
Sprague Dawley rats, C57BL/6J and NOD/SCID-g (NSG, NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from
Charles River Laboratories (Wilmington, MA, USA/Margate,
UK). All animals were housed in cages under standard conditions
(12-hour light/dark cycle). NSG mice were housed in speciﬁc-
pathogen-free conditions. All animals were healthy and
pathogen-free at the start of each study and once each study
had commenced they were monitored daily for any unexpected
adverse effects. Animals were housed in groups and the
numbers per group were determined using power calculations
based on previous studies in which reproducible statistical
differences had been shown.(22) The following power calculation
shows n¼ 8mice/group using the JJN3-NSGmodel to see a 25%
difference in tumor burden (by histological analysis) and a 40%
difference in myeloma-induced bone disease (by mCT analysis).
n ¼ 2ðSDÞ2  fða;bÞ=ðDÞ2
n ¼ 2 2:45ð Þ2  10:5= 4ð Þ2
¼ 7:88 mice per experimental groupð Þ
where the signiﬁcance level is 0.05%, the power level is 90%, the
least practical difference between the groups is 25%, and
estimated coefﬁcient of variance SD/mean¼ 2.45/16¼ 0.15.
Similar calculations were used to determine group numbers in
non–tumor-bearing animals based on previously observed
changes in bone (BMD or trabecular bone fraction [BV/TV]).
Mineral binding affinity
The binding afﬁnities of OX14, ALN, ZOL, RIS, and minodronate
(MIN) were compared by measuring their differential rates of
elution from hydroxyapatite (HAP) columns using a fast protein
liquid chromatography (FPLC) system similar to that previously
described.(23)
FPPS inhibition assay
The inhibitory activity of OX14 was compared to ALN, ZOL, RIS,
and MIN in a FPPS inhibition assay as previously described.(24,25)
The IC50 values are based on preincubation protocols.
Journal of Bone and Mineral Research PHARMACOLOGICAL PROFILE OF OX14, A NOVEL HIGHLY POTENT BISPHOSPHONATE 1861
In vivo evaluation of OX14 and comparator
bisphosphonates as inhibitors of bone resorption
based on metaphyseal BMD
The antiresorptive potency of OX14 was measured by its
effect on increasing BMD compared to ALN, ZOL, RIS, and
MIN in a growing rat model adapted from the Schenk
assay.(26,27) These studies were performed at the Procter &
Gamble Health Sciences Center, Mason, OH, USA from 2007
to 2010, as part of the program of screening new
bisphosphonates. Male Sprague Dawley rats (6 weeks old,
weighing 120 to 150 g) were randomized into groups (n¼ 6)
based on body weight. All groups received treatment by
subcutaneous (s.c.) injection at the same time daily for
7 days. The ﬁrst treatment was on day 0, and the last
treatment on day 6, with animals euthanized by cervical
dislocation on day 7. BMD of the proximal metaphysis of the
right tibia was analyzed using dual-energy X-ray analysis
(DXA) using a Hologic QDR-4500 densitometer (Hologic, Inc.,
Waltham, MA, USA). Efﬁcacy of each bisphosphonate was
expressed as percentage change from the vehicle control
group. The dose that increased BMD 20% greater than the
control was determined via a logistic dose-response rela-
tionship (SAS Institute, Inc., Cary, NC, USA), which estimates
an efﬁcacy value using animals in the study, and for
comparison of bisphosphonates across studies. Data from
compounds run in multiple studies was averaged.
In vivo evaluation of short-term (24-hour) skeletal
retention of OX14 and comparator bisphosphonates,
based on urinary excretion
It is known that bisphosphonates are rapidly taken up by the
skeleton after parenteral administration, and the portion that is
not bound to bone is cleared by the kidneys and appears in the
urine within a few hours. This provides a convenient way of
assessing skeletal uptake as the portion of an administered dose
that is not excreted within 24 hours. Male Sprague Dawley rats
(6 weeks old, weighing 120 to 150 g) were randomized into
groups based on weight, and ﬁtted with i.v. femoral catheters.
Prior to i.v. dosing, each rat was given a single oral dose of 2.5mL
saline to increase initial urine output. Doses of ALN, ZOL, MIN,
RIS, and OX14 (18 to 72mg P/kg) were given in various
combinations and relative concentrations via an i.v. femoral
catheter, which was then ﬂushed with 2.5mL non-heparinized
saline. Rats were then immediately placed inmetabolism caging
and urine was collected for 0 to 24 hours. At the end of urine
collection, the metabolism caging was rinsed with 10mL of
sterile water to collect any urine that had not yet reached the
collection container. Collected urine was analyzed for the
simultaneously administered bisphosphonates, by employing
ion-pairing, reverse-phase, gradient HPLC, with tandem mass
spectrometry detection. Brieﬂy, urine samples were prepared by
dilution in water containing 100mM dimethylhexylamine
(ion pairing reagent) and 2H4-RIS was added as an
internal standard. Prepared samples were injected onto a
2-mm 50-mm C18 column and separated using a rapid water:
acetonitrile gradient and constant modiﬁer composition of
10mM ammonium formate, 10mM dimethylhexylamine, and
0.4% formic acid. Chromatographic efﬂuent was passed into the
ion source of a Sciex API5000 triple quadrupole mass
spectrometer, operated in negative ion mode and employing
selected-reaction-monitoring, for selective detection of each
bisphosphonate. In this, the ﬁrst quadrupole mass analyzer
sequentially transmitted the [M-H]– ion corresponding to each
targeted bisphosphonate into a collision cell, from which a
bisphosphonate-characteristic fragment ion (neutral loss of
m/z 82) was selected to pass through the second mass analyzer,
for detection. This approach enabled speciﬁc detection of each
bisphosphonate, even in the presence of closely related
compounds and high concentrations of urine matrix compo-
nents, allowing simultaneous quantiﬁcation of these co-
administered compounds. With appropriate sample dilution,
accurate measurements were achieved over a 0.1-mg/mL to
10-mg/mL range, employing analytical calibration curves
created from a cocktail containing each bisphosphonate, and
the 2H4-RIS internal standard. Measurement accuracy was
assured by also analyzing quality control samples, consisting
of naive rat urine, fortiﬁed with known concentrations of
bisphosphonate reference standards. Analytical recoveries were
consistently in the 95% to 105% range. Bisphosphonate
concentrations measured in urine were multiplied by the
mass of urine collected for each time-segment, and these results
were added together across the 24-hour period for each rat,
yielding the absolute urinary excretion for each bisphospho-
nate. The percentage excretion data for each bisphosphonate
whether given individually or in combinationwas averaged from
all studies performed (OX14, n¼ 6; ALN, n¼ 9; ZOL, n¼ 6; RIS,
n¼ 42; and MIN, n¼ 3).
In vivo OX14 dose response study in mice
Female C57BL6mice (7 to 8weeks old, weighing 18 to 24 g)were
randomized into six groups (n¼ 8/group) based on weight and
treated at the same time on each day twice a week s.c. with PBS
(100mL), ZOL (28.4mg P/kg), RIS (27.1mg P/kg), or three different
doses of OX14 (23, 2.3, and 0.23mg P/kg) for 3 weeks. All animals
were then anesthetized (100% wt/vol isoﬂurane and 2% oxygen
by inhalation) for cardiac bleeding and euthanized by cervical
dislocation. Tibias were then assessed by mCT and histological
analyzes as described below (see Assessment of bone integrity).
An in vivo therapeutic study comparing OX14 to ZOL in a
murine model of myeloma
Female NSG mice (7 to 8 weeks old, weighing 19 to 23g) were
randomized based on weight into four groups (n¼ 8/group).
Group 1was a non–tumor-bearing control group (naive). Groups 2
to 4 were injected via the tail vein with 1 106 JJN3 cells and then
treated twiceaweek s.c. fromthe timeof tumor cell injection for the
duration of the study with vehicle control (PBS, group 2), ZOL
(28.4mg P/kg, group 3), or OX14 (23mg P/kg, group 4). At the ﬁrst
signs of morbidity (after 3 weeks) all animals were anesthetized
(100% wt/vol isoﬂurane and 2% oxygen by inhalation) for cardiac
bleeding and euthanized by cervical dislocation. Bone disease and
tumor burden were assessed as described below (see Analysis of
tumour burden).
Assessment of bone integrity
At euthanasia, the right tibias were dissected free of soft tissue
and ﬁxed in 10% formalin before mCT analysis was used to
measure the percentage of BV/TV. Tibias were scanned on a
Skyscan 1272 (Bruker, Kontich, Belgium) at 4.3mm with a
0.7-degree rotation step, reconstructed using NRecon (v.
1.6.9.4; Bruker) and analyzed using CTAn (v. 1.12; Bruker). The
number and area of cortical bone lesions (pixels2) were
assessed by taking the mCT datasets, removing the trabecular
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bone and then volume-rendering the datasets to create 3D
models using Drishti (version 1.0; ANUVizlab, Canberra,
Australia), followed by analysis of three different sides of the
bone using ImageJ software (version 1.47; NIH, Bethesda, MD,
USA; https://imagej.nih.gov/ij/). After decalciﬁcation, wax
embedding, and sectioning of the tibias, the numbers of
osteoclasts (following tartrate-resistant acid phosphatase
[TRAP] staining) were assessed using OsteoMeasure Advanced
Bone Histomorphometry Video System (Osteometrics, Inc.,
Decatur, GA, USA) and standard histomorphometricmethods.(28)
Analysis of tumor burden
Tumor burden was assessed on sections of tibias that had been
stainedwith hematoxylin and eosin, where the distinct morphology
of the myeloma cells distinguishes them from normal marrow. The
proportion of bone marrow occupied by the myeloma cells was
assessed using OsteoMeasure and expressed as a percentage of the
whole bone section area as described.(22) Tumor burden was also
assessed inbonemarrowﬂushesof the left femorabyﬂowcytometry
using an anti-human HLA-ABC-APC antibody and an isotype-
matched control (R&D Systems, Minneapolis, MN, USA) as
described.(29,30)
Statistical analysis
Statistical signiﬁcance was determined using the Holm-Sidak
test, a Mann-Whitney test, or a Kruskal-Wallis test with a
Dunn’s multiple comparisons test calculated using GraphPad
Instat version 6.0b (GraphPad Software, Inc., La Jolla, CA, USA).
All data are expressed with error bars representing standard
error of the mean (SE) unless otherwise stated.
Results
OX14 has lower HAP binding characteristics and short-
term (24-hour) skeletal retention dynamics than
bisphosphonates currently used clinically, and is highly
potent at inhibiting osteoclastic bone resorption
To assess the mineral binding characteristics of OX14 compared
to clinically relevant bisphosphonates, each compound was run
separately on a HAP column (Fig. 1A). The retention time for
OX14 (6.17 0.08min) was signiﬁcantly lower (p< 0.0001) than
for ALN, ZOL, RIS or MIN.
The skeletal uptake of OX14 in vivo compared to other
bisphosphonates was assessed by measuring its excretion into
the urine of rats (n¼ 6) after i.v. dosing. After i.v. injection, the
percentage of the dose of OX14 excreted over the ensuing
24 hours was greater than for all of the comparator bi-
sphosphonates. The rank order for increasing excretion was ALN
(22.5% 3.6%), ZOL (27.95% 3.18%), RIS (34.91% 9.3%), MIN
(44.80% 1.6%), and OX14 (52.85% 3.82%) (Fig. 1B). The
numbers of animals dosed with each compound ranged from
three to 42. The results obtained from these and other studies
have shown that the skeletal retention of individual bi-
sphosphonates appear to be similar, regardless of whether
Fig. 1. OX14 has a lowbone-binding afﬁnity and is highly potent at inhibiting FPPS. (A) Retention of OX14 compared to other bisphosphonates on a HAP
column over time. (B) Percentage urinary excretion of ALN, ZOL, RIS, MIN, and OX14 collected from 0 to 24 hours after i.v. injection. (C) FPPS inhibition
assay of OX14 compared to other bisphosphonates. (D) The dose of ALN, ZOL, RIS, MIN, and OX14 (mg P/kg) that increased BMD greater than 20%
compared to vehicle control in a growing rat model (proximal tibial metaphysis). Data are presented as mean SE (except 1B which is mean standard
deviation) and signiﬁcance compared with OX14 is indicated, where p< 0.05, p< 0.01, p< 0.001, and p< 0.0001.
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the drugs are given individually, in pairs, or given all together, even
at different relative doses, implying that there is no signiﬁcant
binding competition among the bisphosphonates under the
conditions used. For example, when RIS was given over a 10-fold
dose range 0.1, 0.5, and 1mg, the % excretion was 38.1 5.6,
45.1 1.0, and 43.0 1.8, respectively. Similar values were
obtained when RIS was co-dosed with equal or greater amounts
of ALN or ZOL (43.2 2.6), or with MIN or OX14 (32.5 0.1).
It should be noted that these studies used doses more than
100-fold lower than those at which skeletal saturation might be
expected to happen, based on reported studies including in
vitro binding studies.(31,32)
Overall, the HAP binding and urinary excretion data both
consistently indicated that OX14 binds less avidly to bone than
the other bisphosphonates tested. These results are summarized
in Fig. 1B and Table 1.
The potential cellular potency of OX14was initially assessed in
an FPPS inhibition assay in vitro, where it was shown to have
similar potency (IC50¼ 2.6 nM) to ZOL, RIS, and MIN, and to be
signiﬁcantly more potent than ALN (p< 0.0001) (Fig. 1C). The
antiresorptive potency of OX14 was then tested in vivo and
compared to ALN, ZOL, RIS, and MIN by assessing (all six mice in
each group) the BMD increase in a growing rat model. OX14 was
shown to have a similar potency to ZOL, RIS, and MIN, and to be
signiﬁcantly more potent than ALN (p< 0.0001) (Fig. 1D). These
results are summarized in Table 1.
Evaluation of different doses of OX14 in vivo compared
to clinically relevant bisphosphonates
In non–tumor-bearing mice OX14 increased BV/TV as assessed
(all eight mice in each group) by mCT (Fig. 2A, B) and was as
effective as ZOL and RIS when given at the same dose. However,
lower doses of OX14 (2.3 and 0.23mg P/kg)were not signiﬁcantly
different from the vehicle control group. Despite this, osteoclast
numbers on the trabecular bone surface were signiﬁcantly
reduced with all compounds except for the lowest dose OX14
group (0.23mg P/kg) when compared to the vehicle control
group (Fig. 2C). A similar trend was observed when the
osteoclast perimeter on the trabecular bone perimeter was
assessed (Fig. 2D); however, neither of the lower doses of OX14
produced signiﬁcant reductions compared to the vehicle
control. The variability in assessment of osteoclasts, and the
variability in animals, is greater than the variability in assessment
of BMD. The trends are consistent with decreases in osteoclasts
correlating with the increases in bone mass. In addition, we
analyzed the number of osteoblasts on the trabecular bone
surface (Fig. 2E). A signiﬁcant reduction in osteoblasts was only
observed in the ZOL-treated group. Therefore, taking all the data
into account, the signiﬁcant differences in BV/TV between the
vehicle and bisphosphonate groups is likely to be due to the
reduction of bone turnover caused by the inhibition of
osteoclastic bone resorption in the bisphosphonate-treated
groups with no inhibition caused in the vehicle-treated group.
OX14 does not reduce tumor burden but prevents
osteolytic disease in JJN3-bearing NSG mice
To assess the effects of OX14 in a disease setting we treated
JJN3-bearing NSG mice with OX14 and compared its effects to
ZOL (Figs. 3 and 4). We assessed (all eight mice in each group)
the effect of OX14 treatment on tumor burden by histological
analysis (Fig. 3Ai–iv, B) and ﬂow cytometric analysis (Fig. 3C).
Histological analysis showed a signiﬁcant reduction in tumor
Table 1. Summary of Data on the Bisphosphonates Studied, Showing Binding Afﬁnities of HAP Columns, 24-hour Skeletal Uptake in
Rats, Inhibition of FPPS in Vitro, and Increases in BMD in Vivo
Bisphosphonate Formula
HAP affinity (mean
retention
time/min)
Skeletal retention (%
of administered
dose)a
FPPS
(IC50)b
Dose required to increase BMD by
20% greater than control (mg
P/kg)c
Alendronate 17.5 0.14 77.5 3.60 330.4 57 1.52
Zoledronate 12.53 0.1 72.05 3.18 4.1 0.07 0.08
Risedronate 9.97 0.18 65.1 9.31 5.7 0.4 0.45
Minodronate 10.33 0.18 55.2 1.6 1.9 0.01 0.11
OX14d 6.17 0.08 47.15 3.82 2.46 0.01 0.30
aCalculated as dose administered minus urinary excretion over 24 hours.
bAfter preincubation.
cThe mg P/kg dose that increased BMD 20% greater than the control.
d(1-ﬂuoro-2-(imidazo-[1,2-a]pyridin-3-yl)-ethyl-bisphosphonate).
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burden in the ZOL-treated group (p< 0.05) compared to the
tumor control group (JJN3). Interestingly, ﬂow cytometric
analysis showed no signiﬁcant reduction in tumor burden
with either OX14 or ZOL compared to the tumor control group
(JJN3). However, a signiﬁcant reduction in osteoclast number
was observed when tumor mice were treated with OX14
(p< 0.05) or ZOL (p< 0.05) (Fig. 3D). OX14 inhibited osteoclastic
bone resorption to the same extent as ZOL, with osteoclast
numbers similar to those seen in non–tumor-bearing mice
(vehicle).
Fig. 2. Evaluation of different doses of OX14 in vivo compared to two clinically established bisphosphonates. (A) Representative mCT images of
transverse sections of tibias from C57Bl/6 mice treated for 3 weeks with vehicle (100mL PBS s.c. 2/week) (i), ZOLa (28.4mg P/kg s.c. 2/week) (ii), RISa
(27.1mg P/kg s.c. 2/week) (iii), or different doses of OX14a–c (23, 2.3, or 0.23mg P/kg s.c. 2/week, and iv, v, and vi, respectively). (B)mCT analysis of BV/TV
(%). (C) Histological analysis of the number of osteoclasts on the trabecular bone surfaces (Oc.N/mm Tb). (D) Histological analysis of osteoclast surface on
the trabecular bone surfaces (Oc.Pm/Tb.Pm, %). (E) Histological analysis of the number of osteoblasts on the trabecular bone surfaces (Ob.N/mm Tb).
Data are presented as mean SE and signiﬁcance compared with the vehicle control, where p< 0.05 and p< 0.01.
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mCT analysis revealed that both OX14 (p< 0.05) and ZOL
(p< 0.001) prevented the osteolytic disease which was observed
in the tumor control group (Fig. 4). Cortical bone lesions were
signiﬁcantly reduced (Fig. 4A, B) and the BV/TV was signiﬁcantly
higher (Fig. 4C) in tumor-bearingmice treatedwithOX14 (p< 0.001)
or ZOL (p< 0.0001) compared to the tumor control group.
In addition, for all the above in vivo studies no adverse side
effects (loss or gain of weight, liver toxicity, or death) were
Fig. 3. OX14 reduces osteoclast numbers in JJN3-bearing NSG mice. (A) Representative histology images of longitudinal and insets of tibias from NSG
mice, at the end stage of disease (3 weeks postinjection of tumor cells), injected with vehicle (naive) (i), 1 106 JJN3 cells (JJN3) (ii) or JJN3 cells, and
treated with ZOL (JJN3þZOL) (iii) or OX14 (JJN3þOX14) (iv). Insets below show the endocortical (box a) bone regions. (B) Histological analysis of the
percentage of tumor burden in tibias. (C) Flow cytometric analysis from femoral bone marrow ﬂushes (vi) of the percentage of tumor burden. (D) The
number of osteoclasts on the cortico-endosteal surface (Oc.N/mm Ec). Data are presented as mean SE and signiﬁcance from the nontumor control
group (naive) is indicated, where p< 0.05.
1866 LAWSON ET AL. Journal of Bone and Mineral Research
observed, indicating that OX14 has a similar safety proﬁle to
other bisphosphonates.
Discussion
In this series of studies we have evaluated the properties of
OX14, a new bisphosphonate compound designed to have
lower bone binding dynamics and a high antiresorptive
potency.
Over the years many hundreds of different bisphosphonates
have been made and more than a dozen have been registered
for clinical use for various indications in various countries. One
of the gratifying advances in recent years has been the
elucidation of the molecular mechanisms of action through
which bisphosphonates act. This has led to the recognition that
the pharmacological effects of bisphosphonates as inhibitors of
bone resorption appear to depend upon two key properties:
their afﬁnity for bone mineral, and their inhibitory effects on
osteoclasts. Thus, although different bisphosphonates share
many pharmacological properties, every bisphosphonate has a
speciﬁc and often unique proﬁle, based on its mineral binding
afﬁnity and biochemical actions. In the case of nitrogen-
containing bisphosphonates such as those studied herein, their
biochemical potency is highly dependent on their inhibitory
Fig. 4. OX14 prevents osteolytic disease in JJN3-bearing NSG mice. (A) Representative longitudinal and transverse mCT images of tibias from NSGmice,
at the end stage of disease, injected with vehicle (naive) (i), 1 106 JJN3 cells (JJN3) (ii) or JJN3 cells, and treated with ZOL (JJN3þZOL) (iii) or OX14
(JJN3þOX14) (iv). (B)mCT analysis of the number of cortical bone lesions. (C)mCT analysis of BV/TV (%). Data are presented asmean SE and signiﬁcance
from the nontumor control group (naive) is indicated, where p< 0.05, p< 0.01, p< 0.001, and p< 0.0001.
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activity (IC50) on their main enzyme target, FPPS. The
pharmacological differences among bisphosphonates may be
of practical clinical importance,(33) for example in the degree and
duration of reduction of bone turnover, which may inﬂuence
how long to treat patients with individual drugs.
One concept to emerge from these considerations is whether
there might be value in designing compounds with somewhat
reduced afﬁnity for bone to enhance their potential direct anti-
tumor effects, while reducing their long-term retention in bone,
which has been thought to be possibly associated with adverse
events. OX14 is an example of applying this concept.(34)
Here we have shown that the binding afﬁnity of OX14 to HAP
was lower than that of ALN, ZOL, RIS, and MIN. Furthermore,
OX14 given to rats was excreted into the urine to a greater
extent than ALN, ZOL, RIS, and MIN, indicating lower skeletal
retention over the 24-hour study period. After a single i.v. dose,
there is rapid skeletal uptake within the ﬁrst few hours, and this
determines how much stays in the skeleton over the ensuing
days and weeks.
To assess the antiresorptive potency of OX14 we used a
growing rat model where it was as effective as ZOL, RIS, and MIN
at increasing BMD. Similarly, in non–tumor-bearing mice, OX14
was as effective as ZOL and RIS at increasing BV/TV. In a murine
model of myeloma-induced bone disease, OX14 was shown to
prevent the development of osteolytic lesions but not to reduce
tumor burden. Interestingly ZOL was shown to signiﬁcantly
inhibit tumor burden by histological analysis of tibial sections.
However, ﬂow cytometric analysis of tumor burden in the ZOL-
treated JJN3 mice did not show a signiﬁcant reduction
compared to the tumor control. Because the JJN3-NSG model
is an aggressive short-term model, it is perhaps not that
surprising that no anti-tumor effects were observed for OX14,
and perhaps a less aggressive longer-term model would be
more suitable to use to assess any nonskeletal effects of the
bisphosphonates in future studies.
Interestingly, OX14 is closely related to MIN, with ﬂuorine
substituted for a hydroxyl group at the R1 position. This
profoundly alters its properties in terms of reducing its mineral
binding with a modest reduction in its IC50 on FPPS. MIN has
emerged as probably the most potent bisphosphonate to be
approved for clinical use by this FPPS measure, but is only used
in Japan.(35,36) This illustrates how apparently small differences
in chemical structure can produce large changes in pharmaco-
logical properties, as has been observed with many other
apparently closely related bisphosphonates.
There is an increasing realization that bisphosphonates have
an extensive range of biological actions in addition to their
well-established effects on bone resorption. Examples of
observed clinical beneﬁts outside the ﬁeld of bone diseases
include a reduction in mortality observed with ZOL in the
Horizon trial.(16,17) Other observational studies have shown a
reduction in mortality after hip fracture in patients receiving
oral bisphosphonates,(15) a reduction of myocardial infarctions
in rheumatoid arthritis patients treated with bisphospho-
nates,(18) and improved survival of patients who had received
a bisphosphonate prior to admission to an intensive care
unit.(19) Administration of oral bisphosphonates may also be
associated with a reduction in deaths from colon cancer.(20,21)
The pharmacology underlying these potential effects of
bisphosphonates needs to be understood, but in theory
many of these effects are likely to result from the known
inhibitory effects of bisphosphonates on the mevalonate
pathway and the consequent effects on protein prenylation
and intracellular signaling pathways in key tissues. For
example, the ability of bisphosphonates to prolong the
survival of mesenchymal stem cells and to enhance DNA
repair after irradiation are dependent on the mevalonate
pathway.(37)
Bisphosphonates have an overall excellent safety proﬁle. The
development of new and even more potent compounds with
lower bone-binding dynamics, such as OX14, offer promising
opportunities for use in these emerging and novel applications.
A key question will be whether the lower bone-binding
properties will offer real pharmacological advantages.
One recent example of the potential utility of nonskeletal
effects of OX14 is its effectiveness in preventing experimentally
induced inﬂammatory colitis.(38)
In summary, OX14 is a new, highly potent bisphosphonate
with reduced bone binding properties compared with other
clinically relevant bisphosphonates. This renders OX14 an
attractive candidate for clinical development for its potential
skeletal or nonskeletal beneﬁts. A full evaluation of its potential
will require further studies of its possible uses and safety proﬁle.
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